Clinical Report: Patient Satisfaction in Relapsing-Remitting Multiple Sclerosis

Overview

Self-administration of subcutaneous ofatumumab at home is associated with improved patient satisfaction compared to other high-efficacy therapies for relapsing-remitting multiple sclerosis. Despite its benefits, fewer than 25% of patients are offered this option, indicating a need for better shared decision-making in treatment selection.

Background

Multiple sclerosis (MS) affects millions globally and requires long-term management to improve quality of life. The introduction of various disease-modifying therapies (DMTs) has expanded treatment options, yet patient satisfaction with these therapies remains under-evaluated. Understanding patient preferences and experiences is crucial for optimizing adherence and treatment outcomes.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Self-administration of subcutaneous ofatumumab leads to better patient-reported outcomes regarding burden and therapeutic impact.
• Less than 25% of patients are offered home self-administration of high-efficacy therapies.
• Patient preferences are increasingly recognized as critical in therapeutic decision-making.
• Factors such as administration setting and autonomy significantly influence patient satisfaction and adherence.
• Comprehensive evaluations of patient satisfaction with high-efficacy therapies are lacking.

Clinical Implications

Healthcare providers should consider patient preferences and the option for home self-administration when discussing treatment plans for MS. Enhancing shared decision-making can lead to improved patient satisfaction and adherence to therapy.

Conclusion

The findings highlight the importance of integrating patient-reported outcomes into treatment decisions for MS. Addressing gaps in the availability of self-administration options can enhance patient satisfaction and overall treatment experience.

References

1. Blood Cancer Journal, 2025 -- Assessment of the safety and effectiveness of subcutaneous isatuximab combined with carfilzomib and dexamethasone in individuals with relapsed/refractory multiple myeloma: findings from the Phase 2 IZALCO trial
2. Clinical Rheumatology, 2023 -- Efficacy and Retention of Subcutaneous Abatacept for Rheumatoid Arthritis in Routine Clinical Settings Across Germany, Austria, and Switzerland: A Two-Year Analysis by Treatment Line and Serological Status
3. Brain, 2023 -- Evaluating the Efficacy of Immune Reconstitution Therapies in Multiple Sclerosis: A Comparative Analysis
4. First-Line Use of Higher-Efficacy Disease-Modifying Therapies in Multiple Sclerosis: Canadian Consensus Recommendations, 2025
5. Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis, 2025
6. Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis, 2024
7. Drugs - Real World Outcomes — Evaluation of Adherence to Interferon-β-1b and Interferon-β-1a Before and After the Launch of the BETACONNECT® Autoinjector: A Retrospective Cohort Analysis
8. First-Line Use of Higher-Efficacy Disease-Modifying Therapies in Multiple Sclerosis: Canadian Consensus Recommendations | Canadian Journal of Neurological Sciences | Cambridge Core
9. Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis - ScienceDirect
10. Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis | BMC Neurology | Full Text